Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

Administration and Scoring Variance on the ADAS-Cog

(2017) Donald J. Connor et al.   JOURNAL OF ALZHEIMERS DISEASE

Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

(2017) Robert E. Becker et al.   JOURNAL OF ALZHEIMERS DISEASE

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease

(2015) Philip Scheltens et al.   Alzheimers & Dementia

Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road—a global, multicenter trial

(2015) Robert Lasser et al.   Alzheimers & Dementia

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

(2014) Jeffrey Cummings et al.   Alzheimers & Dementia

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

(2012) Kevin Mullane et al.   BIOCHEMICAL PHARMACOLOGY

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Stopping Alzheimer's Before It Starts

(2012) G. Miller   SCIENCE

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Why So Few Drugs for Alzheimers Disease? Are Methods Failing Drugs?

(2010) R. E. Becker et al.   Current Alzheimer Research

Alzheimers Disease Drug Development in 2008 and Beyond: Problems and Opportunities

(2008) Robert Becker et al.   Current Alzheimer Research